Search results
Results From The WOW.Com Content Network
In 2005, Merck spent $21 million US [62] to retain John S. Martin Jr., a former US District Judge for the Southern District of New York, and colleagues at Debevoise & Plimpton LLP, to investigate Vioxx study results and communications conducted by Merck. The report, which Merck called the "Martin Report", was published in February 2006.
Pharmaceutical powerhouse Merck (NYS: MRK) has agreed to settle a class action lawsuit filed in Missouri by Vioxx customers, the company announced yesterday. Those who filed the lawsuit had ...
In 2005, Lanier represented Carol Ernst in a lawsuit against Merck & Co., a pharmaceutical company and manufacturer of Vioxx, an anti-inflammatory drug used to treat osteoarthritis and acute pain conditions. Ernst was married to Robert Ernst, a former marathon runner who died after taking the medication.
Merck [14] $650 million Medicare fraud, kickbacks Zocor, Vioxx, Pepsid: False Claims Act, Medicaid Rebate Statute 2007 Purdue Pharma [15] $601 million Off-label promotion Oxycontin: False Claims Act 2010 Allergan [16] $600 million Off-label promotion Botox: False Claims Act, FDCA 2010 AstraZeneca [17] $520 million Off-label promotion, kickbacks ...
Merck & Co.'s Vioxx Recall. ... The company lost an estimated $725 million in sales and ended up paying out billions in lawsuits. In 2008, Merck settled most of its product-liability lawsuits for ...
Merck (NYS: MRK) is one of the oldest pharmaceutical companies on the planet -- but history counts for little in an industry perennially fueled by new innovations and scientific breakthroughs.
About 50,000 people sued Merck, claiming they or their family members had suffered medical problems such as heart attacks or strokes after taking Vioxx. [172] In November 2007, Merck agreed to pay $4.85 billion to settle most of the pending Vioxx lawsuits. [173]
After joining Merck & Co. as general counsel, he directed the company's defense against litigation over the anti-inflammatory drug Vioxx. Frazier is the first African American man to lead a major pharmaceutical company (part of the Fortune 500 companies). [ 1 ]